Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 47 citing articles:

Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer
Aarti Bhatia
The Cancer Journal (2022) Vol. 28, Iss. 5, pp. 331-338
Closed Access | Times Cited: 96
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Mı́riam Molina-Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine
Valentin Van den Bossche, Hannah Zaryouh, Marianela Vara-Messler, et al.
Drug Resistance Updates (2022) Vol. 60, pp. 100806-100806
Closed Access | Times Cited: 68
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
Sainiteesh Maddineni, John L. Silberstein, John B. Sunwoo
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 5, pp. e004693-e004693
Open Access | Times Cited: 49
Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
Lindsey Carlsen, Kelsey E. Huntington, Wafik S. El‐Deiry
Cancers (2022) Vol. 14, Iss. 4, pp. 1028-1028
Open Access | Times Cited: 41
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
Satyam Singh, Sushabhan Sadhukhan, Avinash Sonawane
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188967-188967
Closed Access | Times Cited: 34
Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice
Hamad Ghaleb Dailah, Abdullah Abdu Hommdi, Mahdi Dafer Koriri, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24559-e24559
Open Access | Times Cited: 10
Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
Chenhang Yu, Qiang Li, Yu Zhang, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 31
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
Pashtoon Murtaza Kasi, Manuel Afable, Cameron J. Herting, et al.
The Oncologist (2023) Vol. 28, Iss. 12, pp. 1034-1048
Open Access | Times Cited: 16
The role of monoclonal antibodies in the treatment of pancreatic and colon cancers
Soumya Dakshinamurthy
Elsevier eBooks (2025), pp. 389-412
Closed Access
Preclinical investigation of anti-tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma
Chaeyeon Kim, Mina Han, Gamin Kim, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial
Paolo Bossi, Andrea Alberti, Cristiana Bergamini, et al.
European Journal of Cancer (2025), pp. 115379-115379
Closed Access
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy
Massimo Claudio Fantini, Philip M. Arlen, Kwong Y. Tsang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study
Myeong Geun Choi, Gun Woo Son, Mi Young􀀁 Choi, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008585-e008585
Open Access | Times Cited: 4
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance
Samuele Tardito, Serena Matis, Maria Raffaella Zocchi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7131-7131
Open Access | Times Cited: 4
The HER family as therapeutic targets in colorectal cancer
Peng Ye, Yiran Wang, Ruiqi Li, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 174, pp. 103681-103681
Closed Access | Times Cited: 17
Immunotherapy in the Treatment of Cancer: Today and Tomorrow
Gökçen Ömeroğlu Şi̇mşek
Current Molecular Biology Reports (2024)
Closed Access | Times Cited: 3
TGF-β Signaling Pathway-Based Model to Predict the Subtype and Prognosis of Head and Neck Squamous Cell Carcinoma
Lian Zheng, Zhenjie Guan, Miaomiao Xue
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 15
EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
Ritu Chaudhary, Robbert J.C. Slebos, Leenil C. Noel, et al.
Cancer Research Communications (2023) Vol. 3, Iss. 5, pp. 896-907
Open Access | Times Cited: 8
Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma
Wei‐Ming Wang, Sisi Yang, Shu-Hui Shao, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 13
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
Carminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 13
The prognostic impact of the immune signature in head and neck squamous cell carcinoma
Hasan Baysal, Vasiliki Siozopoulou, Hannah Zaryouh, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas
Kwong Y. Tsang, Massimo Fantini, Sharon Mavroukakis, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3037-3037
Open Access | Times Cited: 10
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors
Sara Piccinelli, Rizwan Romee, Roman M. Shapiro
Seminars in Hematology (2023) Vol. 60, Iss. 1, pp. 42-51
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top